老虎證券

BUZZ-Capricor rises on FDA's priority review for Duchenne muscular dystrophy-related cell therapy

Reuters
03-04
BUZZ-Capricor rises on FDA's priority review for Duchenne muscular dystrophy-related cell therapy

** Shares of Capricor Therapeutics CAPR.O rise ~12% to $15.30 premarket

** Co says the U.S. FDA has granted Priority Review to its drug to treat a heart condition associated with Duchenne muscular dystrophy (DMD)

** DMD cardiomyopathy is a heart muscle disease that can develop in individuals with the genetic condition causing progressive muscle weakness

** FDA is set to decide on the cell therapy, deramiocel, by August 31

** 'Priority review' status reduces the review timeline to six months from the time of filing, compared to a standard review timeline of 10 months

** Up to last close, stock nearly tripled in the past 12 months

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10